[ad_1]
A medical device recently brought to Guam offers new treatment options for brain-related conditions such as depression, anxiety-related depression, obsessive-compulsive disorder, and smoking addiction.
According to a foundation press release, the Todu Guam Foundation plans to use a transcranial deep magnetic stimulator at its health and wellness center in Tamuning.
On January 27, 2023, Manuel employees who conducted the 2023 homeless time point survey in a northern village visit Yigo’s Gil Breeze subdivision.
Made by Massachusetts-based company Brainsway, the device sits on a person’s head and uses a magnetic field to influence brain activity.
According to the press release, the treatment is non-invasive and useful when other treatments are ineffective.
“Our mental and behavioral health challenges on Guam require creative strategies and actions,” said foundation president and co-founder Lena Calvo Rodriguez in a press release. I’m here.
Calvo-Rodriguez said in the release: “With the support of USDA Guam and his office in Honolulu, the funds awarded to our company have enabled the purchase and installation of his BrainsWay Deep TMS device, the first in Guam.”
High school and college students interested in health care and social work have the opportunity to learn more about career areas in English.
According to a press release, transcranial magnetic stimulation is the method accepted by the U.S. Department of Veterans Affairs, Medicare, and the National Health Maintenance Organization.
In August 2018, the U.S. Food and Drug Administration cleared the sale of Brainsway’s device for the treatment of obsessive-compulsive disorder.
“Transcranial magnetic stimulation shows potential to help patients suffering from depression and headaches,” Dr. Carlos Peña, director of the Division of Neurological and Physical Medical Devices at the FDA’s Center for Medical Devices and Radiation Health, said in a press release. stated in the release.
The Todu Guam Foundation continues its mission to provide accessible healthcare through its annual medical outreach service, offering free sc…
“Today’s marketing authorization provides another option for OCD patients who have not responded to conventional therapies,” Peña added in the release.
In 2008, the FDA authorized the marketing of TMS as a treatment for major depression, and in 2013, approved the use to include TMS to treat pain associated with certain migraine headaches, according to an FDA press release. Expanded.
In a foundation press release, Calvo-Rodriguez said, “We have developed a relationship with Brainsway that ensures that the Todu Guam Foundation will be responsive to the unique needs of our community and the Micronesian region.
“We look forward to making this resource available to underserved communities because they are cornerstones of our mission. We look forward to serving our partners and veterans,” said Calvo-Rodriguez. Added.
Corrections and Clarifications: This story has been updated to reflect that Todu Guam Foundation is the correct name for the organization. …
This device is part of the Foundation’s Mental/Behavioral Health Program. The program plans to launch the MindCare project in the first quarter of 2023, according to a foundation press release.
[ad_2]
Source link
